Overview

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic

Status:
Completed
Trial end date:
2016-06-11
Target enrollment:
Participant gender:
Summary
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Quintiles, Inc.
Treatments:
Antibodies, Monoclonal
Docetaxel
Gefitinib
Osimertinib
Tremelimumab